Ameen A.
- Country
- Germany
- Department
- Hämatologie/Onkologie
Research Overview
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA -Mutant, Hormone Receptor-Positive, HER2 -Negative Locally Advanced or Metastatic Breast Cancer
- Preoperative FOLFOX Versus Postoperative Risk-Adapted Chemotherapy in Locally Advanced Rectal Cancer: A Phase III Randomized Trial
- Phase IIIb Randomized Multicenter Open-Label Trial of Atezolizumab and Bevacizumab Versus Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
Data & Insights
Has run more than one trial at 94 of 224 partner sites.
Specializations
Rectal Cancer Treatment
The investigator specializes in treating intermediate and high-risk rectal cancer and locally advanced rectal cancer, with particular focus on developing innovative therapeutic approaches.
- Organ Preservation Strategies
- Radiotherapy Optimization
- Combined Treatment Modalities
The investigator explores various treatment combinations including short course radiotherapy and chemoradiotherapy protocols.
Surgical Innovation
Key interests include the development and evaluation of risk-adapted surgical approaches for rectal cancer treatment, with emphasis on timing and necessity of surgical intervention.
- Selective Surgery Protocols
- Local Excision Techniques
- Risk-Stratified Treatment
The investigator focuses on pre-operative and post-operative treatment strategies to optimize surgical outcomes.
Treatment Response Assessment
Expertise in evaluating disease-free survival and monitoring treatment responses through advanced clinical assessment methods.
- Response Monitoring
- Survival Analysis
- Treatment Adaptation
The investigator specializes in MRI-defined risk assessment and treatment response evaluation.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.